Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Tesla Stock Still Looks Worth Buying

Tesla’s biggest fan still thinks Tesla stock can jump tremendously over the next five years. I believe the shares are worth buying for long-term investors.

Trading Near Its All-Time High, Can Intel Stock Go Higher?

Intel is having a strong year, up about 11% year-to-date. With that in mind, can Intel stock keep this momentum going further into 2020?

Here’s a Slightly Safer Way to Bet on Lyft Stock   

If you believe ride-hailing will continue to grow in popularity, but are worried about Lyft and Uber ever making money (a real possibility!), why not hedge your bet by investing in one of the leading players in automated driving technology?

2020 Could Be the Year Cronos Comes Alive

Cronos Group reports its fourth-quarter and full-year results on Feb. 27. Owners of CRON stock shouldn’t expect much in the near term.

What’s It Going to Take for Zillow to Get Back to $150?

Zillow Group’s latest partnership with regional homebuilders could help Z stock and ZG stock get to $150. Here’s why.

If You Like Fuel Cell Energy, Bloom Energy Might Be The Safer Bet

While FCEL stock is an interesting play, FuelCell Energy reported disappointing Q4 2019 results, making Bloom Energy the safer play.

7 Reasons to Own Taylor Morrison Stock

Taylor Morrison recently got out of Chicago. Here are seven reasons why you should still own Taylor Morrison stock. 

Beyond Meat Stock Could Be in Trouble Due to Rising Legal Concern

Beyond Meat faces mounting legal pressures that could provide owners of Beyond Meat stock with indigestion moving forward.

The Odds of Freeport-McMoRan Stock Hitting $60 Again Are Good

The coronavirus could affect Freeport-McMoRan in the short term, but the long-term demand for copper should be good for FCX stock.

What Inovio Pharma’s $100 Million Addition to Its Shelf Offering Means for INO Stock 

Like many pharmaceutical companies, Inovio loses a lot of money. As of September 30, 2019, it had an accumulated deficit of $702 million, which means it’s lost $702 million over its history.